Last reviewed · How we verify

NCT04277416

Survivorship and Effectiveness of the Ortho Development® Entrada™ Hip System for Total Hip Arthroplasty

ENROLLING BY INVITATION Last updated 13 October 2022
What this trial tests

trial testing Total Hip Arthroplasty in Total Hip Replacement in 250 participants. Enrolling by invitation.

Timeline
28 February 2020
Primary endpoint
31 December 2031
31 December 2032

Quick facts

Lead sponsorOrtho Development Corporation
StatusENROLLING BY INVITATION
Study typeOBSERVATIONAL
Enrollment250
Start date28 February 2020
Primary completion31 December 2031
Estimated completion31 December 2032
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Ortho Development Corporation

Who can join

Adults 18 to 80, any sex, with Total Hip Replacement or Total Hip Arthroplasty. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate Implant survival based on removal or intended removal of any component of the Entrada™ Hip System at five years of follow-up.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Total Hip Arthroplasty

Trials testing the same drug.

Other recruiting trials for Total Hip Replacement

Currently open trials in the same condition.

Other Ortho Development Corporation trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04277416.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing